Key Highlights

  • Cash, cash equivalents and fixed-term deposits totaled $149 million as of September 30, 2026.
  • Cash fell $62 million from $211 million at December 31, 2025.
  • The company realigned its operating model, targeting cash runway into the second half of 2028.
  • HEAL-101 reduced triglycerides by 76% in a disease model in preclinical work.

Cellectis (Euronext Growth: ALCLS, Nasdaq: CLLS) reported financial results for the third quarter ended September 30, 2026, and provided a Business update on November 12, 2026. The company develops genetic medicines and is now focused on in vivo gene editing. The quarter brought a realigned operating model, a substantial reduction in cash over the year and preclinical data for two liver-directed programs, HEAL-101 and HEAL-201.

Pipeline and Preclinical Data

Chief Executive André Choulika said the company's teams have been focused on a new in vivo gene editing direction since September. After a single administration, HEAL-101 edited the human APOC3 gene at rates of up to 70% in a humanized liver model, with editing restricted to the liver. The company said HEAL-101 consistently reduced triglycerides by 76% in a disease model.

Cellectis plans to start an investigator-initiated trial of HEAL-101 in China. HEAL-201 achieved a reduction of more than 90% in plasma PCSK9 in a humanized liver mouse model, and the company expects preliminary clinical data for HEAL-201 in the first half of 2028.

Cash, Spending and Runway

Cash, cash equivalents, restricted cash and fixed-term deposits were $149 million as of September 30, 2026, compared with $211 million at December 31, 2025, a decline of $62 million. The company said restricted cash of $2.3 million is included in that total.

Research and development expenses were $108.8 million for the nine months, up from $69.1 million, an increase of $39.7 million. The company reported a consolidated net loss attributable to shareholders of $101.1 million, or $1.00 per share, for the nine-month period, and an adjusted net loss of $95.2 million, or $0.95 per share. The company said it is focusing its cash spending on its pipeline and expects a runway into the second half of 2028.

Sector Context

In vivo gene editing aims to correct disease at the source by delivering editing tools directly into the body, which can avoid the costly ex vivo cell Manufacturing used in some earlier therapies. The field is early, and the main questions concern delivery, durability and safety in patients.

Cellectis's move toward liver-targeted programs puts it in a competitive area that includes several developers working on cardiometabolic gene editing. Its results will be judged against those programs as data emerge.

Cellectis's research spending has risen sharply over the year, with R&D expenses of $108.8 million for nine months compared with $69.1 million a year earlier. That increase helps explain both the larger net loss and the decline in cash, and the company's realigned model is intended to reduce spending while supporting its priority programs.

Risks and What Lies Ahead

The company's cash declined by $62 million in nine months, and its runway into the second half of 2028 depends on its realigned spending plan. Early preclinical results do not guarantee clinical success, and the transition from preclinical work to human trials carries substantial uncertainty.

Investors should watch the China trial start, the HEAL-201 clinical data in 2028 and the company's cost reductions under the realigned model. The conference call scheduled for November 13 is expected to give more detail on the operating changes.

The company's dependence on preclinical data means that the next clinical readouts carry substantial weight. Preliminary human data for HEAL-201 are not expected until the first half of 2028, so the company's near-term value will depend on continued progress in the preclinical and early trial work it has described.

Final Word

Cellectis reported $149 million in cash after a $62 million decline in nine months, while it shifts its pipeline toward in vivo gene editing. The preclinical data for HEAL-101 and HEAL-201 support the direction, but clinical proof is still ahead. The company's ability to stay within its runway while advancing the programs will be the main test in its coming reports.